Saatja: HERFELD Stefan <
[email protected]>
Saadetud: 08.11.2019 15:30
Adressaat: <
[email protected]>; <
[email protected]>;
<
[email protected]>; Tanel Kiik <
[email protected]>; SM Info <
[email protected]>
Koopia: JANKELEVITSH Leon <
[email protected]>
Teema: Changes in pharmacy retail market legislation entering into force
on 1 April 2020
Dear Gentlemen,
With this letter the PHOENIX group would like to address the serious
concern related to major changes in Estonian law affecting whole pharmacy
retail market and to protection of significant investments of Germany
headquartered PHOENIX group in the Republic of Estonia.
PHOENIX group is a leading pharmaceutical trader in Europe. In
pharmaceutical wholesale PHOENIX group is active in 26 European countries
supplying pharmacies and medical institutions with medicines and other
health products. In pharmacy retail PHOENIX group operates more than
2,500 pharmacies in 14 countries most of them operate under the
corporate brand BENU.
We entered the Estonian market after acquisition of Finnish Tamro group
in 2001. During the years of activity in Estonia, we have developed
pharmaceutical wholesale activity and invested into and built up an
operation of more than 80 BENU pharmacies. Today, PHOENIX group through
BENU Apteek Eesti OÜ is one of the major service providers to the
Estonian people.
With the great concern, we have observed changes in Estonian legislation
regarding pharmaceutical sector. In 2014 and 2015 amendments were adopted
to the Estonian Medicinal Products Act stipulating that wholesalers of
medicinal products are prohibited from having holdings in general
pharmacies, or having any other dominant influence over holdings that
have an activity licence of a general pharmacy. In addition, a
requirement was established that a pharmacist must hold more than 50% of
the shares of the pharmacy company.
The above-mentioned amendments have a significant impact on the
activities of the PHOENIX group in Estonia and endangers the availability
of medicines in Estonia. As a consequence of the amendments to the
Medicinal Products Act, PHOENIX group must divest its holdings in the
pharmacies operating in Estonia by 1 April 2020 at the latest, or wind up
their activities. Such regulation can be considered entailing
expropriation of investments of foreign investors, incl. the PHOENIX
group.
Unfortunately, the amendments to the Medicinal Products Act do not
prescribe any compensation for compulsory dissolution of the operation of
general pharmacies belonging to wholesalers or financial support to
pharmacists for buying the pharmacies for fair value. As far as the
PHOENIX group is aware, no realistic steps have been taken to solve the
specified problem by drafting an Act covering the compensation package to
investors deriving from expropriation or supporting buyers/pharmacists.
The fact that general pharmacies have to be shut down in the absence of
pharmacists interested in the acquisition of a holding therein is an
inevitable consequence of the regulation. Furthermore, it is extremely
unlikely that the sufficient number of pharmacists will have the motive
and financial capability to acquire the pharmacies from a current owner.
Consequently, foreign investors are unable to get any fair compensation
for their investments.
Furthermore, no analysis has been made to specify how the availability of
medicines is affected by the law amendments and guaranteed after 1 April
2020. We are seriously concerned that enforcement of the law amendments
may lead to closing almost 300 pharmacies in Estonia as on 1 April 2020.
I kindly ask the Social Affairs Committee of Estonian Parliament one more
time to evaluate and recognise the risks that may occur to the patients
and to availability of medicines that may become evident after 1 April
2020 when almost 300 pharmacies may be forced to end their activities.
Additionally, consequences deriving from illegal expropriation must be
considered as the investors shall have the right to file a compensation
claim against the Estonian State. I truly believe that it is possible to
find a solution best for patients and people of Estonia, but also for
investors.
Thank you very much for the consideration you will give to this letter
and I remain at your disposal should you need any further information
(contact person in Estonia: Mr Leon Jankelevitsh, Managing Director Tamro
Baltics, e-mail
[email protected], phone +37256 220 133).
Best Regards,
Stefan Herfeld
Member of the Executive Board Retail
PHOENIX Pharma SE
Pfingstweidstraße 10-12
68199 Mannheim
GermanyPhone +49 621 8505-251
PHOENIX Pharmahandel GmbH & Co KGPfingstweidstrasse 10 - 12D-68199
Mannheim
Sitz der Hauptniederlassung: MannheimRegistergericht: Amtsgericht
Mannheim HRA 3551
USt.-IdNr.: DE811737260
Glaeubiger-Identifikationsnummer: DE43ZZZ00000032466
Persoenlich haftende Gesellschafterin: PHOENIX Verwaltungs
GmbHZweigniederlassung DeutschlandRegistergericht: Amtsgericht Mannheim
HRB 718800
HauptniederlassungSitz Vaduz/LiechtensteinHandelsregister Liechtenstein
Nr. FL-0002.468.204-0
Geschaeftsfuehrung: Sven Seidel (Vorsitzender), Helmut Fischer, Marcus
Freitag, Frank Große-Natrop, Stefan Herfeld
Diese E-Mail und alle Anhaenge enthalten vertrauliche und rechtlich
geschuetzte Informationen, die ausschliesslich fuer den Gebrauch des
Adressaten bestimmt sind. Das unerlaubte Kopieren, die unbefugte
Weitergabe oder sonstiger ungenehmigter Gebrauch der E-Mail nebst den
Anhaengen sind nicht gestattet. Sollten Sie nicht der richtige Adressat
sein oder die E-Mail irrtuemlich erhalten haben, informieren Sie bitte
den Absender unverzueglich telefonisch oder per E-Mail und vernichten
diese E-Mail und alle Anhaenge sowie etwaige Kopien und Sicherungskopien.
Vielen Dank.
This e-mail message and all attachments transmitted with it may contain
legally privileged and confidential information intended solely for the
use of the addressee. If you are not the intended recipient or have
received this e-mail in error, you are hereby notified that any
dissemination, distribution, copying, or other use of this message or its
attachments is strictly prohibited. If you have received this message in
error, please notify the sender immediately by telephone or by electronic
mail, and delete this message and all copies and backups thereof. Thank
you.